Skip to content
10-K

Annual Report

NAVIDEA BIOPHARMACEUTICALS, INC.

0001437749-23-008054

← back to feed
Filed
Mar 27, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2022 · Mar 17, 2023 32.85M sh
Capex FY 2022 · Dec 31, 2022 $63.09K
Capex FY 2022 · Dec 31, 2021 $25.22K
Operating Cash Flow FY 2022 · Dec 31, 2022 −$8.99M
Operating Cash Flow FY 2022 · Dec 31, 2021 −$10.22M
Cash And Equivalents FY 2022 · Dec 31, 2022 $2M
Cash And Equivalents FY 2022 · Dec 31, 2021 $4.23M
Stockholders Equity FY 2022 · Dec 31, 2022 −$8.44M
Stockholders Equity FY 2022 · Dec 31, 2021 −$106.56K
Current Liabilities FY 2022 · Dec 31, 2022 $9.94M
Current Liabilities FY 2022 · Dec 31, 2021 $5.3M
Total Liabilities FY 2022 · Dec 31, 2022 $12.51M
Total Liabilities FY 2022 · Dec 31, 2021 $6.02M
Current Assets FY 2022 · Dec 31, 2022 $3.2M
Current Assets FY 2022 · Dec 31, 2021 $5.38M
Total Assets FY 2022 · Dec 31, 2022 $4.37M
Total Assets FY 2022 · Dec 31, 2021 $6.64M
Eps Basic FY 2022 · Dec 31, 2022 −$0.56
Eps Basic FY 2022 · Dec 31, 2021 −$0.40
Sga Expense FY 2022 · Dec 31, 2022 $7.96M
Sga Expense FY 2022 · Dec 31, 2021 $7.45M
Rd Expense FY 2022 · Dec 31, 2022 $5.97M
Rd Expense FY 2022 · Dec 31, 2021 $5.14M
Net Income FY 2022 · Dec 31, 2022 −$15.18M
Net Income FY 2022 · Dec 31, 2021 −$11.73M
Operating Income FY 2022 · Dec 31, 2022 −$14.05M
Operating Income FY 2022 · Dec 31, 2021 −$12.06M
Gross Profit FY 2022 · Dec 31, 2022 −$119.3K
Gross Profit FY 2022 · Dec 31, 2021 $531.51K
Cost Of Revenue FY 2022 · Dec 31, 2022 $1.94K
Cost Of Revenue FY 2022 · Dec 31, 2021 $0
Revenue FY 2022 · Dec 31, 2022 $65.65K
Revenue FY 2022 · Dec 31, 2021 $531.51K